Original HTML
VIENNA, Sept. 8, 2026 /PRNewswire/ -- Cell-free DNA assembly pioneer, Ribbon Bio, has today announced the appointment of Jay Therrien as Chief Business Officer. Therrien joins Ribbon's executive leadership team where he will lead the company's commercial strategy and growth initiatives.
Therrien brings over two decades of experience building and leading commercial organizations across the life sciences and genomics sectors. Most recently, he served as Chief Commercial Officer at Ultima Genomics and previously held executive leadership roles at IDEX Health & Science, RainDance Technologies, Life Technologies and Illumina. Throughout his career, Therrien has helped launch several breakthrough technologies, including multiplex genotyping, digital PCR and next-generation sequencing platforms, supporting a wide range of genomic applications across the research and clinical markets. As Chief Business Officer, Therrien will lead Ribbon Bio's efforts to expand adoption of its cell-free DNA solutions, with immediate focus on the company's recently launched MiroMine™ kit, which enables customers to access Ribbon Bio's powerful assembly algorithms and cell-free synthesis processes in their own labs.
"After taking a close look at Ribbon's technology, operations and long-term market opportunity, it became clear that the company is uniquely positioned to help shape the future of DNA synthesis, while catalyzing a transition away from legacy cloning methods," said Jay Therrien, Chief Business Officer at Ribbon Bio. "I'm thrilled to join Ribbon at this time, as demand for increasingly intricate DNA molecules continues to grow. It is especially exciting to highlight that using Ribbon's MiroMine kits does not require any unique, single-purpose lab instrumentation or capital equipment. The ability to immediately use the MiroMine™ kit in a lab is one of many reasons we expect a rapid adoption of Ribbon's technology. We look forward to supporting customers as they generate high-fidelity, cell-free DNA constructs in their own labs, freeing themselves from cloning."
"We're delighted to welcome Jay to Ribbon's executive team," said Jodi Barrientos, Chief Executive Officer of Ribbon Bio. "His extensive commercial experience and track record of success will be invaluable as we continue to scale the business and advance our vision for the future of DNA synthesis."
About Ribbon Bio
Ribbon Bio is a cell-free DNA assembly company, transforming access to high-fidelity DNA molecules. By producing DNA independent of bacterial-mediated processes, Ribbon sidesteps many of the limitations inherent to traditional plasmid-based approaches, delivering purer DNA without endotoxin contamination, faster production timelines, and greater reliability at scale. This cell-free approach unlocks a new level of freedom and flexibility, enabling researchers and developers to access DNA molecules of unprecedented length, structure, and complexity, eliminating long-standing bottlenecks which constrain innovation. Powered by proprietary algorithms and deep manufacturing expertise, Ribbon is democratizing the use of synthetic DNA, ensuring its place as a foundational tool for next-generation science that will improve the health of both humanity, and the planet. For more information, visit us at www.ribbonbio.com.
SOURCE Ribbon Bio
Share this article
Original Summary
<p>VIENNA, Sept. 8, 2026 /PRNewswire/ -- Cell-free DNA assembly pioneer, Ribbon Bio, has today announced the appointment of Jay Therrien as Chief Business Officer. Therrien joins Ribbon's executive leadership team where he will lead the company's commercial strategy and growth initiatives....</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Ribbon Bio Names Jay Therrien Chief Business Officer", "body_html": "<p><strong>VIENNA -- [CURRENT_DATE] --</strong> Ribbon Bio, a cell-free DNA assembly company, has appointed Jay Therrien as Chief Business Officer, tasking him with scaling commercial adoption of its recently launched MiroMine kit.</p><h5>Therrien brings two decades of genomics commercial leadership to Ribbon Bio</h5><p>Therrien most recently served as Chief Commercial Officer at Ultima Genomics and previously held executive posts at IDEX Health & Science, RainDance Technologies, Life Technologies and Illumina. He has led commercial launches spanning multiplex genotyping, digital PCR and next-generation sequencing platforms across research and clinical markets.</p><h5>MiroMine kit requires no proprietary lab equipment, lowering adoption barriers</h5><p>Therrien's immediate focus will be expanding uptake of Ribbon Bio's MiroMine kit, which gives customers direct access to the company's cell-free synthesis processes and assembly algorithms in their own labs. Unlike competing platforms, the kit does not require single-purpose instrumentation or capital equipment investment, a factor Therrien said should accelerate customer onboarding.</p><p>\"Using Ribbon's MiroMine kits does not require any unique, single-purpose lab instrumentation or capital equipment,\" Therrien said, adding that this immediate usability is a key driver behind his expectation of rapid technology adoption.</p><h5>Cell-free method targets legacy bacterial cloning bottlenecks in DNA synthesis</h5><p>Ribbon Bio produces DNA independent of bacterial-mediated processes, aiming to eliminate endotoxin contamination and reduce production timelines compared with traditional plasmid-based cloning. The company positions this cell-free approach as enabling DNA molecules of greater length, structure and complexity for researchers and developers.</p><p>Ribbon Bio CEO Jodi Barrientos said Therrien's commercial track record will support the company's plan to scale operations and advance its DNA synthesis roadmap.</p>", "meta_description": "Ribbon Bio appoints Jay Therrien as Chief Business Officer to drive commercial expansion of its cell-free MiroMine DNA synthesis kit across genomics markets.", "seo_keywords": "Ribbon Bio, Jay Therrien, cell-free DNA, MiroMine kit, DNA synthesis, Chief Business Officer, genomics commercialization", "companies": ["Ribbon Bio", "Ultima Genomics", "Illumina"], "industries": ["Laboratory Equipment"], "markets_regions": ["United States", "Global"], "news_type": ["personnel_appointment", "product_launch"], "products": ["MiroMine kit"], "themes": ["biotech_innovation", "commercial_strategy", "supply_chain"], "events": [], "cta_text": "Learn more about Ribbon Bio's cell-free DNA assembly technology and MiroMine kit.", "learn_more": "http://www.ribbonbio.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
